Apellis Pharmaceuticals, Inc. (APLS) incurred a first-quarter 2024 loss of 54 cents per share, which matched the Zacks Consensus Estimate. The company had incurred a loss of $1.56 per share in the year-ago quarter.Total revenues amounted to $172.3 million in the reported quarter, beating the Zacks Consensus Estimate of $160.5 million. In the year-ago quarter, the company had reported revenues of $44.8 million.The top line skyrocketed 284% year over year, owing to higher sales of Syfovre (pegcetacoplan injec ...